<DOC>
	<DOCNO>NCT00393770</DOCNO>
	<brief_summary>Decreased insulin sensitivity ( e.g . insulin resistance ) hallmark major pathogenic factor type 2 diabetes . It key factor metabolic syndrome - cluster arterial hypertension , obesity , impair glucose tolerance , dyslipidemia , coagulation abnormality , albuminuria increase cardiovascular risk - may precede accompany type 2 diabetes . Insulin function abnormality associate insulin resistance , may major role prevent type 2 diabetes , long-term , diabetes micro- macrovascular complication . Carnitine involved lipid carbohydrate metabolism acetyl-L-carnitine ( ALC ) , intramitochondrial carrier acylic group , may modulate cell fuel substrate utilization . Studies find carnitine may improve insulin sensitivity glucose disposal healthy subject patient type 2 diabetes . A recent study also find prim constant infusion acetyl-L-carnitine ( ALC ) may increase glucose utilization type 2 diabetic patient , possibly restore glycogen synthase activity . Thus , design Acetylcarnitine insulin resistance study , pilot , sequential , longitudinal study aim assess whether acetyl-carnitine may improve insulin function lipid profile patient increase risk type 2 diabetes .</brief_summary>
	<brief_title>Acetylcarnitine Insulin Sensitivity</brief_title>
	<detailed_description>Decreased insulin sensitivity ( e.g . insulin resistance ) hallmark major pathogenic factor type 2 diabetes . Diabetes often related cluster arterial hypertension , obesity , impair glucose tolerance , dyslipidemia , coagulation abnormality , albuminuria increase cardiovascular risk call metabolic syndrome . A reduction insulin-resistance may improve metabolic syndrome , decrease long term onset clinical diabetes incidence important cardiovascular renal complication . In presence insulin resistance alter normal signal adipose tissue consequent reduction absorption use glucose . In subject increase fat mass , mainly visceral , show influence several factor , tumoral necrosis factor alfa ( TNF alfa ) fatty free acid ( FFAs ) , peripheral activity insulin . TNF alfa , key modulator fat metabolism , direct role insulin-mediated homeostasis glucose fatty acid , regulate action lipoprotein lipases fatty acid carrier influence CoA synthesis leptin production , finally , inhibits insulin secretion pancreatic beta cell . Increasing circulate concentration fatty acid , due absence suppression lipolysis due insulin inactivity , contribute peripheral hepatic insulin resistance . It also correlate condition active inflammation , link high incidence atherosclerosis cardiovascular risk , typical diabetes . Other factor , adiponectin resistin , show role glucose metabolism . Adiponectin , protein produce adipocytes , well-known anti-inflammatory anti-atherogenic action , postulate improve insulin sensitivity improvement carbohydrates lipid metabolism . In contrast , resistin seem induce insulin resistance decrease glucose tolerance . Thus , improvement metabolic syndrome , mean increase insulin sensitivity correction correlate lipid carbohydrate metabolism may play primary role prevention type 2 diabetes , long term , may decrease micro- macro-vascular complication . Large prospective trial help u understand cellular mechanism involve metabolic syndrome may useful identify new therapeutic target aim reduce insulin resistance . Carnitine involved lipid carbohydrate metabolism acetyl-L-carnitine ( ALC ) may increase glucose utilization type 2 diabetic patient , possibly restore glycogen synthase activity . ALC mitochondrial carrier acylic group , directly indirectly participate carbohydrate metabolism , act fatty acid glucose oxidation pyruvate dehydrogenase ( PDH ) . PDH form enzymatic complex ( PDC ) catalyze irreversible reaction carbohydrate oxidation , control phosphorylation-dephosphorylation cycle , Pyruvate Dehydrogenase Kinase use ATP phosphorylate PDH cause inactivation , Pyruvate Dehydrogenase Phosphatase dephosphorylates PDH inactivating . Kinase activate increase ratio intramitochondrial acetylCoA/CoA , see condition high fatty acid level . The consequent reduction PDC activity , dramatically decrease glucose oxidation . Carnitine participate trans-esterification , form acetylcarnitine . By mean catch acylic group , decrease ratio acetylCoA/CoA , indirectly stimulate PDC activity favour pyruvate oxidation glucose . Thus acetylcarnitine consider modulator substrates utilization cell , consequence metabolism lipid carbohydrate . Several study demonstrate carnitine contributes improvement insulin sensitivity glucose utilization healthy subject type 2 diabetic . Thus interesting confirm hypothesis acetylcarnitine may improve insulin sensitivity patient risk type 2 diabetes verify improvement associate component metabolic syndrome . Primary aim To evaluate insulin sensitivity ( e.g . Glucose disposal rate euglycemic hyperinsulinemic clamp ) 40 patient normal morning fast glucose increase risk type 2 diabetes mellitus . Secondary aim - To evaluate drug effect sit systolic/diastolic blood pressure , lipid profile , morning fasting glucose postprandial glucose . - To assess correlation insulin sensitivity serum inflammatory marker ( Erythrocyte Sedimentation Rate , C-reactive protein ) insulin , leptin adiponectin level - To assess treatment tolerability Design study This sequential longitudinal study . Potentially eligible patient baseline evaluation follow parameter : Clinical Systolic/diastolic blood pressure , Heart rate , Body weight ( BW ) , B.M.I. , Total body water ( TBW ) * , Fat-free mass ( FFM ) ** , Fat mass ( FM ) *** Metabolic Fasting morning blood glucose ; oral glucose tolerance test Insulin , leptin , adiponectin level Lipid profile Total , VLDL HDL cholesterol , total triglyceride , Apolipoprotein A B Inflammatory marker Erythrocyte Sedimentation Rate , C-reactive protein plasma TNF alfa Patients satisfy inclusion/exclusion criterion insulin sensitivity evaluate euglycemic hyperinsulinemic clamp enter six month treatment period Acetylcarnitine 2 g/day . At end treatment period 2 month treatment withdrawal , baseline parameter , include insulin sensitivity , evaluate . No change diet concomitant treatment ( particular diuretic , ACE inhibitor , angiotensin II receptor antagonist , dihydro non-dihydro calcium channel blocker , statin ) introduce throughout whole study period . * Calculated Hume Weyers formula : TBW male = ( 0.2968 x weight kg ) + ( 0.1948 x height cm ) - 14.0129 TBW female = ( 0.1838 x weight kg ) + ( 0.3446 x height cm ) - 35.2701 ** FFM = TBW/0.73 *** FM = BW - FFM</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>least three Relatives type 2 diabetes Age 40 65 year Systolic diastolic pressure ≥ 140 ≥90 mmHg respectively Body mass index ≥25 men ≥24 woman Triglycerides ≥200 mg/dl Serum creatinine ≤1.5 mg/dl , proteinuria ≤ 0.5g/24h Capacity understand scope risk study write informed consent Concomitant treatment steroid , antiinflammatory immunosuppressive drug , drug act insulin sensitivity and/or insulin secretion , particularly glitazones oral hypoglycemic drug Treatment Lacetylcarnitine six month study Previous concomitant treatment metformin legal incapacity and/or circumstance render patient unable understand nature , scope possible consequence trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Risk type 2 diabetes</keyword>
</DOC>